These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 9816008)
41. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes. Asano T; McIntyre BW; Bednarczyk JL; Wygant JN; Kleinerman ES Oncol Res; 1995; 7(5):253-7. PubMed ID: 8534931 [TBL] [Abstract][Full Text] [Related]
42. Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients. Sone S; Utsugi T; Tandon P; Yanagawa H; Okubo A; Ogura T Cancer Immunol Immunother; 1990; 30(6):357-62. PubMed ID: 2302725 [TBL] [Abstract][Full Text] [Related]
43. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. Murray JL; Kleinerman ES; Cunningham JE; Tatom JR; Andrejcio K; Lepe-Zuniga J; Lamki LM; Rosenblum MG; Frost H; Gutterman JU J Clin Oncol; 1989 Dec; 7(12):1915-25. PubMed ID: 2479721 [TBL] [Abstract][Full Text] [Related]
44. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide. Koff WC; Showalter SD; Hampar B; Fidler IJ Science; 1985 Apr; 228(4698):495-7. PubMed ID: 2984772 [TBL] [Abstract][Full Text] [Related]
45. Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. Creaven PJ; Cowens JW; Brenner DE; Dadey BM; Han T; Huben R; Karakousis C; Frost H; LeSher D; Hanagan J J Biol Response Mod; 1990 Oct; 9(5):492-8. PubMed ID: 2254761 [TBL] [Abstract][Full Text] [Related]
46. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. Sone S; Mutsuura S; Ogawara M; Tsubura E J Immunol; 1984 Apr; 132(4):2105-10. PubMed ID: 6699409 [TBL] [Abstract][Full Text] [Related]
47. In vitro and in vivo canine mononuclear cell production of tumor necrosis factor induced by muramyl peptides and lipopolysaccharide. Kurzman ID; Shi F; MacEwen EG Vet Immunol Immunopathol; 1993 Sep; 38(1-2):45-56. PubMed ID: 8256437 [TBL] [Abstract][Full Text] [Related]
48. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714 [TBL] [Abstract][Full Text] [Related]
49. Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. Koff WC; Fidler IJ; Showalter SD; Chakrabarty MK; Hampar B; Ceccorulli LM; Kleinerman ES Science; 1984 Jun; 224(4652):1007-9. PubMed ID: 6426057 [TBL] [Abstract][Full Text] [Related]
50. Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes. Sone S; Tandon P; Utsugi T; Ogawara M; Shimizu E; Nii A; Ogura T Int J Cancer; 1986 Oct; 38(4):495-500. PubMed ID: 3093390 [TBL] [Abstract][Full Text] [Related]
51. Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages. Utsugi T; Nii A; Fan D; Pak CC; Denkins Y; van Hoogevest P; Fidler IJ Cancer Immunol Immunother; 1991; 33(5):285-92. PubMed ID: 1868486 [TBL] [Abstract][Full Text] [Related]
52. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. Kleinerman ES; Snyder JS; Jaffe N J Clin Oncol; 1991 Feb; 9(2):259-67. PubMed ID: 1988574 [TBL] [Abstract][Full Text] [Related]
53. Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined. ten Hagen TL; van Vianen W; Bakker-Woudenberg IA J Infect Dis; 1995 Feb; 171(2):385-92. PubMed ID: 7844375 [TBL] [Abstract][Full Text] [Related]
54. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ. Pahl JH; Kwappenberg KM; Varypataki EM; Santos SJ; Kuijjer ML; Mohamed S; Wijnen JT; van Tol MJ; Cleton-Jansen AM; Egeler RM; Jiskoot W; Lankester AC; Schilham MW J Exp Clin Cancer Res; 2014 Mar; 33(1):27. PubMed ID: 24612598 [TBL] [Abstract][Full Text] [Related]
55. Effect of liposome-muramyl tripeptide combined with recombinant canine granulocyte colony-stimulating factor on canine monocyte activity. Kurzman ID; Cheng H; MacEwen EG Cancer Biother; 1994; 9(2):113-21. PubMed ID: 7529085 [TBL] [Abstract][Full Text] [Related]
56. A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers. Venkatakrishnan K; Kramer WG; Synold TW; Goodman DB; Sides E; Oliva C Eur J Clin Pharmacol; 2012 Oct; 68(10):1347-55. PubMed ID: 22460239 [TBL] [Abstract][Full Text] [Related]
57. Differential release of TNF-alpha, IL 1, and PGE2 by human blood monocytes subsequent to interaction with different bacterial derived agents. Fidler IJ; Nii A; Utsugi T; Brown D; Bakouche O; Kleinerman ES Lymphokine Res; 1990; 9(4):449-63. PubMed ID: 2090873 [TBL] [Abstract][Full Text] [Related]
58. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367 [TBL] [Abstract][Full Text] [Related]
59. Preferential induction of TNF-alpha and IL-1beta and inhibition of IL-10 secretion by human peripheral blood monocytes by synthetic aza-alkyl lysophospholipids. Gan XH; Bonavida B Cell Immunol; 1999 May; 193(2):125-33. PubMed ID: 10222054 [TBL] [Abstract][Full Text] [Related]